Effect of antianginal drugs in stable angina on predicted mortality risk after surviving a myocardial infarction: A preliminary study (METRO)

American Journal of Cardiovascular Drugs

Volumn 9, Issue 5, 2009, Pages 293-297

  Iyengar, Shamanna S ^a   Rosano, Giuseppe M C ^b  

^a ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANGINA PECTORIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NICORANDIL; NITRATE; TRIMETAZIDINE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE FREE SURVIVAL; DRUG EFFECT; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; HYPERTENSION; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STABLE ANGINA PECTORIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANGINA PECTORIS; CARDIOVASCULAR AGENTS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MYOCARDIAL INFARCTION; ODDS RATIO; RETROSPECTIVE STUDIES; RISK; SURVIVAL; TREATMENT OUTCOME;

EID: 70349755365     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11316840-000000000-00000     Document Type: Article

References (19)

1. Abrams J. Chronic stable angina. N Engl J Med 2005; 352: 2524-2533
2. Pfeffer MA, McMurray JJV, Veazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure: left ventricular dysfunction or both. N Engl J Med 2003; 349: 1893-1906 (Pubitemid 37409706)
3. Opie LH. The metabolic vicious cycle in heart failure. Lancet 2004; 364: 1733-1734 (Pubitemid 39488043)
4. Kowalczyk E, Kopff M, Kowalski J, et al. Effect of cardiovascular drugs on adenosine deaminase activity. Angiology 2008; 59: 740-744
5. Poole-Wilson P, Lubsen J, Kirwan B, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial) randomised controlled trial. Lancet 2004; 364: 849-857 (Pubitemid 39221062)
6. The IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359: 1269-1275
7. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing b-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999; 281: 1927-1936 (Pubitemid 29242807)
8. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month post-discharge death in an international registry. JAMA 2004; 291: 2727-2733 (Pubitemid 38725422)
9. Psaty BM, Furberg CD. Contemplating ACTION: long acting nifedipine in stable angina. Lancet 2004; 364: 817-818
10. Banach M, Rysz J, Goch A, et al. The role of trimetazidine after acute myocardial infarction. Curr Vasc Pharmacol 2008; 6: 282-291
11. Marzilli M, Focardi M, Affinito S, et al. The rationale of metabolic treatment in ischaemic heart disease. Arch Med Sci 2007; 3: S25-9 (Pubitemid 351155253)
12. Caminiti G, Marazzi G, Vitale C, et al. Metabolic management of diabetic patients with ischaemic heart disease. Arch Med Sci 2007; 3: S30-7 (Pubitemid 351155254)
13. El-Kady T, El-Sabban K, Gabali M, et al. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy. Am J Cardiovasc Drugs 2006; 5: 271-278
14. Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005; 91: 161-165
15. Fragasso G, Perseghin G, De Cobell F, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatinine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006; 27: 942-948
16. Beardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low dose dobutamine in ischemic cardiomyopathy. Eur Heart J 2001; 22: 2164-2170 (Pubitemid 33139462)
17. Lu C, Dabrowski P, Fragasso G, et al. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998; 82: 898-901 (Pubitemid 28467367)
18. Lopaschuk GD. Pharmacologic rationale for trimetazidine in the treatment of ischemic heart disease. Am J Cardivasc Drugs 2003; 3 Suppl. 1: 21-26 (Pubitemid 36432368)
19. Katz MH. Multivariable analysis: a primer for readers of medical research. Ann Intern Med 2003; 138: 644-645